Current Beat

Jun | 13 | 2024
Press Release
Remix Therapeutics™ to Present Preclinical Data Demonstrating Anti-Tumor Activity of REM-422 in AML at the European Hematology Association (EHA) 2024 Congress
REM-422, a first-in-class MYB mRNA degrader, induces anti-tumor activity across multiple preclinical models of AML Watertown, Mass. (June 13, 2024) – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease, will deliver a poster presentation demonstrating the therapeutic potential of REM-422, a potent, […]
Filter by: All
Media Contact
Lisette Steele
Verge Scientific Communications

What We've Been Up To